Brind.

Gossamer Bio regained full global rights from Chiesi, while facing FDA review issues and authorizing a reverse split for Nasdaq compliance.

2 reports, 2 independent Updated Aug 27
Gone quiet
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Gossamer Bio regained full global rights from Chiesi, while facing FDA review issues and authorizing a reverse split for Nasdaq compliance.

Who's involved

What this event is mainly about
ChiesiNasdaqFDA

How it developed

Newest first. Tap a step to see who reported it.
  1. FDA acceptance and reacquisition of rights from Chiesi drive financing milestones.1 source
  2. Gossamer Bio regained global rights from Chiesi but faces FDA review issues and Nasdaq compliance challenges.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • insidermonkey.com
  • benzinga.comGossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate - Gossamer Bio (NASDAQ:GOSS)